Day: November 9, 2022

On July 30, 2012, Zhang, Wei; Chen, Niangen; Huang, Jian; Zhai, Ruirui; Fu, Naiguang published an article.Application of 39512-49-7 The title of the article was Study on synthetic and salifying process of loperamide hydrochloride. And the article contained the following:

To study the preparation of the synthetic process of loperamide hydrochloride, a drug which was widely used in the treatment of acute diarrhea with low side effect. Loperamide hydrochloride was synthesized from 2, 2-diphenyl-4-hydroxybutyric acid-γ-lactone as raw material via ring-opening, SN2 substitution, acidylation, quaternization, condensation and salifying. In the first step, when the reaction time was 24 h and temperature was 25°C, the yield was 81%. In the second step, when the molar ratio of n(SOCl2):n(2,2-phenyl-4-bromobutyric acid)=2:1 and temperature was reflux, the content of 4-bromo-2, 2-diphenylbutyroyl chloride(4) was 97.25%. And the key intermediate dimethyl(tetrahydro-3, 3-diphenyl-2-furylidene)ammonium bromide(5) was obtained with the yield increased from 50%(literature reported) to 68% when the molar ratio of n(4):n(Na2CO3):dimethylamine=1.0:1.2:1.5 and temperature was 0∼5°C. When the molar ratio of n(5):n(4-p-chlorophenyl-4-piperidinol):n(Na2CO3)=1.0:1.2:1.1, loperamide(6) was obtained with yield of 85%. After simple salification, the target compound 1 was synthesized from(6) with the yield of 89.6%. The overall yield was 34% and its structure was characterized by IR, 1H-NMR, 13C-NMR and MS spectra. Some drawbacks in the literature was improved and the method was easy for synthesis and suitable for industrial manufacturing The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Application of 39512-49-7

The Article related to loperamide hydrochloride synthetic salifying process, Pharmacology: Methods and other aspects.Application of 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 30, 2012, Ali, Imran; Gupta, Vinod K.; Singh, Prashant; Negi, Uma published an article.SDS of cas: 39512-49-7 The title of the article was Monitoring of haloperidol and its metabolites in plasma by SPE-RP-TLC spectrometry. And the article contained the following:

We describe a simple and inexpensive SPE-RP-TLC method for the monitoring and anal. of haloperidol and its metabolites in plasma. Anal. was carried out on RP-TLC plates containing C18 silica gel using methanol having 0.001% diethylamine as a mobile phase. The chromatograms were developed up to 10 cm for 65 min at 28 ± 10°C. Detection of haloperidol and its metabolites was done by placing the dried plates in normal glass iodine chamber. The quant. anal. of haloperidol and its metabolites were carried out by using UV-visible spectroscopy at 230 nm. RF values of haloperidol, metabolite I, metabolite II, and metabolite III in plasma samples were 0.22, 0.06, 0.16, and 0.87, resp., and their percentage recoveries were 85.0, 88.0, 87.0, and 77.0, resp. The detection limit of RP-TLC method for haloperidol was 1.0 mg mL-1 and for all the three metabolites I, II, III was 0.8 mg mL-1. The results show that the developed method may be used for higher recovery of drugs under consideration from biol. samples. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).SDS of cas: 39512-49-7

The Article related to biomonitoring haloperidol metabolite solid phase extraction reverse phase tlc, Pharmacology: Drug Metabolism and other aspects.SDS of cas: 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On January 14, 2022, Ghersi, Dario; Genaro-Mattos, Thiago C. published an article.Synthetic Route of 39512-49-7 The title of the article was Identifying Molecular Fragments That Drive 7-Dehydrocholesterol Elevation. And the article contained the following:

Medications having the unwanted side effect of inhibiting 7-dehydrocholesterol reductase (DHCR7), one of the last enzymes in the cholesterol biosynthesis pathway, account for about 300 million yearly prescriptions in the United States. Many of these drugs are currently prescribed to pregnant women. Many DHCR7-inhibiting medications share chem. similarities, which can be the active substructure responsible for the medication affinity to the enzyme. This work highlights a computational strategy to identify enriched fragments in a set of DHCR7-inhibiting medications. The computational approach used here involves systematic fragmentation of mols. using the molBLOCKS tool, followed by enrichment anal. The results of this approach highlight putative pharmacophores that might be responsible for the DHCR7-inhibiting activity of some of these medications. The identification of DHCR7-inhibiting substructures is an important step toward knowledge-based drug development and can improve the neurodevelopmental safety of medications. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Synthetic Route of 39512-49-7

The Article related to cholesterol metabolism 7 dehydrocholesterol pharmacophore molblocks dhcr7, smith lemli opitz syndrome, Pharmacology: Drug Metabolism and other aspects.Synthetic Route of 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Favretto, Donata; Stocchero, Giulia; Nalesso, Alessandro; Vogliardi, Susanna; Boscolo-Berto, Rafael; Montisci, Massimo; Ferrara, Santo D. published an article in 2013, the title of the article was Monitoring Haloperidol Exposure in Body Fluids and Hair of Children by Liquid Chromatography-High-Resolution Mass Spectrometry.Related Products of 39512-49-7 And the article contains the following content:

Background: Haloperidol, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone (HP), one of the most widely used antipsychotics in the treatment of schizophrenia, mania, and other psychiatric disorders, is frequently encountered in cases of unintentional pediatric intoxication because the ingestion of a small amount can cause significant toxic effects in children. For monitoring HP in suspected ingestions, a liquid chromatog.-high-resolution mass spectrometry method has been developed and validated in urine, blood, and hair samples. Methods: The analyte was extracted from 1 mL blood or urine by liquid/liquid extraction and from 5 mg of hair by micropulverized extraction; gradient elution on an Atlantis T3 column was realized using HP-d4 as an internal standard Pos. ion electrospray ionization and high-resolution mass spectrometry determination were performed in an Orbitrap mass spectrometer. Results: The method exhibited a r > 0.999 in the studied ranges (0.1-50 ng/mL in urine and blood and 0.1-50 ng/mg in hair) and a limit of quantification of 0.1 ng/mL for urine and blood and 0.1 ng/mg for hair; intra-assay and interassay relative SDs were always more than 18%. The method was applied to determine haloperidol in 3 children who were admitted to emergency departments. HP concentrations ranged from 2 to 21 ng/mL in urine, from not detected to 4.9 ng/mL in blood, and from 0.37 to 0.73 ng/mg in hair samples. Conclusions: The utilization of high-resolution/high-accuracy mass spectrometry in full scan mode allowed the identification of HP metabolites in urine and blood, thus unequivocally documenting the exposure to the drug. HP metabolites were structurally characterized by high-resolution multiple mass spectrometry. For the first time, a HP metabolite was detected in hair. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Related Products of 39512-49-7

The Article related to liquid chromatog high resolution mass spectrometry haloperidol metabolite hair, body fluid child intoxication, Pharmacology: Drug Metabolism and other aspects.Related Products of 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On March 12, 2020, Crew, Andrew P.; Hornberger, Keith R.; Wang, Jing; Crews, Craig M.; Jaime-Figueroa, Saul; Dong, Hanqing; Qian, Yimin; Zimmerman, Kurt published a patent.Name: tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate The title of the patent was Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides. And the patent contained the following:

The present disclosure relates to bifunctional compounds, ULM- L-PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the resp. E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacol. activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Name: tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

The Article related to polycyclic targeted protein kinase raf, Pharmaceuticals: Pharmaceutics and other aspects.Name: tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Schinina, Barbara; Martorana, Andrea; Colabufo, Nicola Antonio; Contino, Marialessandra; Niso, Mauro; Perrone, Maria Grazia; De Guidi, Guido; Catalfo, Alfio; Rappazzo, Giancarlo; Zuccarello, Elisa; Prezzavento, Orazio; Amata, Emanuele; Rescifina, Antonio; Marrazzo, Agostino published an article in 2015, the title of the article was 4-Nitro-2,1,3-benzoxadiazole derivatives as potential fluorescent sigma receptor probes.Product Details of 39512-49-7 And the article contains the following content:

New fluorescent derivatives for σ receptors were designed and synthesized. To achieve this purpose, a 4-nitro-2,1,3-benzoxadiazole fluorescent tag was connected through a piperazine linker to a modified skeleton derived from selected σ receptor agonists or antagonists. Compounds 5g, 7b, 7e and 7g displayed high σ1 affinity and low σ1/σ2 selectivity (Kiσ1 ranging from 31.6 nM to 48.5 nM, Kiσ1/σ2 = 5-18), while compound 5d exhibited high σ2 affinity and selectivity (Kiσ2 = 56.8 nM, Kiσ1 > 5000 nM). Binding affinity studies revealed that compounds 5d, 5g, 7b, 7e and 7g showed no affinity towards several receptors including opioid, dopaminergic, serotonergic, adrenergic, muscarinic, histaminergic, N-methyl-D-aspartate (NMDA), NMDA receptor channel, or dopamine and serotonin transporters. The fluorescent properties, cellular uptake and confocal microscopy studies on 5d suggest a potential use of this probe to further clarify the mol. role of σ2 receptor subtypes in normal and cancer cells. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Product Details of 39512-49-7

The Article related to benzoxadiazole derivative sigma receptor probe, Biochemical Methods: Synthesis and other aspects.Product Details of 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 30, 2020, Daerr, Markus; Allmendinger, Lars; Hoefner, Georg; Wanner, Klaus T. published an article.Synthetic Route of 39512-49-7 The title of the article was Synthesis and biological evaluation of fluorescent GAT-ligands based on asymmetric substituted BODIPY dyes. And the article contained the following:

The present study aimed at the development of fluorescent inhibitors addressing the GABA transporters mGAT1-mGAT4 as potential tool compounds in fluorescence based biol. assays. The design of these fluorescent GAT inhibitors followed the structural motifs common for many GAT1-GAT4 inhibitors publicly known except that the lipophilic domain present in this compounds was replaced by a BODIPY moiety to serve as a fluorescent subunit. The fluorescent compounds obtained that way were tested for their inhibitory potencies and subtype selectivities at the four murine GABA transporter subtypes mGAT1-mGAT4 and for their binding affinity for mGAT1. All BODIPY derivatives displayed only low inhibitory potencies and subtype selectivities at the GABA transport proteins mGAT1-mGAT4, as well as low affinities for mGAT1. Still, compounds were found with reasonable binding affinities towards mGAT1 (pKi ∼ 5.0) and inhibitory potencies at mGAT2 and mGAT4 (pIC50 ∼ 5.0). The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Synthetic Route of 39512-49-7

The Article related to fluorescent gat ligand asymmetry bodipy dye, Pharmacology: Structure-Activity and other aspects.Synthetic Route of 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On November 14, 2019, Fyfe, Tim J.; Kellam, Barrie; Sykes, David A.; Capuano, Ben; Scammells, Peter J.; Lane, J. Robert; Charlton, Steven J.; Mistry, Shailesh N. published an article.Quality Control of 4-(4-Chlorophenyl)piperidin-4-ol The title of the article was Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor. And the article contained the following:

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side-effects (EPS) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R whereas clozapine exhibits relatively slow association/fast dissociation Recently, the authors have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side-effects independent of its D2R action. The results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, the authors conducted a structure-kinetic relationship study of haloperidol and reveal that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Quality Control of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to structure pharmacokinetics haloperidol dopamine d2 receptor, Pharmacology: Structure-Activity and other aspects.Quality Control of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On November 15, 2009, Burgey, Christopher S.; Potteiger, Craig M.; Deng, James Z.; Mosser, Scott D.; Salvatore, Christopher A.; Yu, Sean; Roller, Shane; Kane, Stefanie A.; Vacca, Joseph P.; Williams, Theresa M. published an article.Formula: C19H18ClN3O4 The title of the article was Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: Development of novel spiropiperidines. And the article contained the following:

Several novel spiropiperidine-based CGRP receptor antagonists have been developed that maintain good potency and have reduced potential for metabolism The experimental process involved the reaction of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate(cas: 883984-95-0).Formula: C19H18ClN3O4

The Article related to spiropiperidine cgrp receptor antagonist preparation migraine, Pharmacology: Structure-Activity and other aspects.Formula: C19H18ClN3O4

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem